Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, or ALSP for short, is a rare neurologic disorder estimated to affect about 10,000 people in the United States, with similar prevalence in Europe and Japan. The disease generally presents in adults in their forties and is marked by cognitive dysfunction, neuropsychiatric symptoms, and motor impairment. There are currently no approved therapies for the treatment of ALSP, highlighting a significant unmet medical need in this rare condition.
The stock we are bringing to your attention is that of Vigil Neuroscience Inc. (VIGL), a company at the forefront of developing a potential breakthrough therapy for ALSP.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.